Marcin Pustula

Dr. Marcin Pustula

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2019 in Molecules
Verified
Journal Article
Open access
PDF file
KGKatarzyna Guzik
Katarzyna Guzik
MTMarcin Tomala
Marcin Tomala
DMDamian Muszak
Damian Muszak
MKMagdalena Konieczny
Magdalena Konieczny
AHAleksandra Hec
Aleksandra Hec
THTad Holak
Tad Holak
Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or their long half-life. Small-molecule inhibitors of the PD-1/PD-L1 interaction have been highly anticipated as a promising alternative or complementary therapeutic to the monoclonal antibodies (mAbs). Currently, the field of developing anti-PD-1/PD-L1 small-molecule inhibitors is intensively explored. In this paper, we review anti-PD-1/PD-L1 small-molecule and peptide-based inhibitors and discuss recent structural and preclinical/clinical aspects of their development. Discovery of the therapeutics based on small-molecule inhibitors of the PD-1/PD-L1 interaction represents a promising but challenging perspective in cancer treatment.

1 April 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MTMarcin D. Tomala
Marcin D. Tomala
KMKatarzyna Magiera-Mularz
Katarzyna Magiera-Mularz
KKKatarzyna Kubica
Katarzyna Kubica
SKSylwia Krzanik
Sylwia Krzanik
BZBartosz Zieba
Bartosz Zieba
THTad Holak
Tad Holak

Verified
Journal Article
Open access
PDF file
JCJulia Chudzian
Julia Chudzian
ASAnna Szlachcic
Anna Szlachcic
MZMalgorzata Zakrzewska
Malgorzata Zakrzewska
MCMiroslawa Czub
Miroslawa Czub
MPMarcin Pustula
Marcin Pustula
JOJacek Otlewski
Jacek Otlewski
Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor types, including lung or breast cancer. The development of FGF1-targeting molecules with potential implications for the therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment of cancer. In this study we have used phage display selection to find scFv antibody fragments selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones were expressed and characterized with regard to their binding to FGF1 and ability to interfere with FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format, as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective cancer therapy.

1 February 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MPMarcin Pustula
Marcin Pustula
MCMirosława Czub
Mirosława Czub
BŁBeata Łabuzek
Beata Łabuzek
ESEwa Surmiak
Ewa Surmiak
MTMarcin Tomala
Marcin Tomala
THTad Holak
Tad Holak